SCROLL
SCROLL
Your perfect ally for drug discovery
and development
Accelera is a premium tier Contract Research Organization (CRO) working and collaborating
with more than 300 pharmaceutical and biotechnology companies around the world.
About us
We are involved in preclinical research with decades of experience in the international pharmaceutical field helping us to select the best drugs.
We are a Contract Research Organisation (CRO), one of the few Italian companies capable of providing support through all phases of drug research and development, adapting and personalising services and consultancy in accordance with requests.
Our research teams integrate scientific, technological, and regulatory expertise flexible and customized services.
We collaborate internationally with both biotechnology and pharmaceutical companies, as well as with the academic and non-profit world.
Accelera is a subsidiary of the NMS Group.
Our Services as a CRO
Our established scientific experience and flexible, safe, and integrated approach make Accelera the ideal partner for your company to achieve effective, high-quality, and fast results.
We provide scientific advice in special technological areas: from preclinical testing to safety pharmacology and drug interactions, from in vitro tests to radiosynthesis, up to PBPK and PK / PD modelling.
We can also provide support services for New Chemical Entities (NCE) development, biologics as well as new oncology drugs.
General Toxicology
DISCOVER MORE
Reproductive toxicology
DISCOVER MORE
Safety Pharmacology
DISCOVER MORE
Isotope Chemistry & Drug Disposition
DISCOVER MORE
Bioanalysis
DISCOVER MORE
Regulatory Support
DISCOVER MORE
Our Commitment
Accelera, one stop shop service provider for drug development, offers a unique background, built on years as part of global R&D of Pfizer, Pharmacia & Upjohn and Farmitalia Carlo Erba.
Accelera provides customer tailored services to select the best drug candidates and develop NCEs, NBEs, Biosimilars, and Cell Based Therapies, running optimised IND enabling studies, as well as reproductive toxicology and ADME studies
Fully compliant to international guidelines, Accelera has a strong track record of regulated activities recognized by the major Agencies, including EMA, FDA, KFDA, MHLW.
Look into future
Business Area
Molecule type
Accelera’s services meet various needs. Our solutions are segmented by molecule type, by the company/institution to which the client belongs, and by the therapeutic area in which it operates, that is, the pathology that the molecule under development is meant to treat.
Identifies the type of molecule (test item) developed by the client and which will be the subject of the studies offered by Accelera’s services. Depending on your molecule type we will choose the most suitable services to create the best drug.
Molecules are divided as follows:
● Small molecule
● Large molecule – Biologic
● Biosimilar
● Advanced therapy medicinal products (ATMP)
● Vaccine
Industry
Identifies the type of customer in terms of institution/company. According to the category to which you belong, Accelera will vary the approach and the services offered, taking the key drivers typical of that specific area as a benchmark.
These are the different clients:
● Start up
● Biotech
● Small pharma
● Mid – Large pharma
● Medical device
Therapeutic area
Identifies the macro-area in terms of pathologies of interest and / or the therapeutic target of the molecule developed by the company or the institution.
These are Accelera’s therapeutic areas of excellence, in which we have gained extensive experience:
● Oncology
● Autoimmune
● CNS
Latest News & Events
Visit Accelera Team at the SOT 2023 Annual Meeting in Nashville, Tennessee (March 19-23)
Visit Accelera Team
at the SOT 2023 Annual Meeting in Nashville, Tennessee
March 19 – 23
Booth #1214
Visit our booth for an overview of our services
(Click the title for the complete article)
Accelera sponsor del 21° congresso nazionale SITOX – Bologna (20-22 Febbraio 2023)
Accelera è Sponsor del 21° congresso nazionale SITOX che si svolgerà a Bologna il giorno 21 febbraio (dalle 11.00 alle 12.00), presenterà il poster “Valutazione preclinica della tossicità a carico del SNC nel soggetto pediatrico: tecniche istologiche in neonati di ratto”.
nella sessione P3 Farmaci
Numero del poster: P3/1
(Click the title for the complete article)
NMS Group S.p.A. names Sidney Shin-Yi Dung as Chief Operating Officer to drive growth
NMS Group S.p.A. (NMS Group), the largest oncological R&D company in Italy, announces the appointment of Ms. Sidney Dung as Chief Operating Officer with immediate effect. Ms. Dung, currently a member of the Company’s Executive Leadership Team and Chief of Staff, will take primary responsibility for accelerating groupwise operational performance, continuing the transformation of the business model of each subsidiary and implementing the strategic vision and values of the company, in collaboration with leaders across the firm in her new role as COO.
(Click the title for the complete article)
Latest Events
Latest News
Need information?
Welcome and Check out our new motion picture!